When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

Recent research highlights the significant underuse of disease-modifying therapies for sickle cell disease, despite their ...

Contrary to misconceptions among medical professionals and patients alike, individuals born with sickle cell trait (SCT) show no risk of experiencing the acute pain crises known to occur with ...

Undergoing a bone marrow transplant during adolescence, but not in adulthood, may lower the risk of stroke with SCD, a mouse ...

Bone marrow transplantation (BMT) can potentially cure sickle cell disease, an inherited and painful blood disorder, but ...

A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative ...

The following is a summary of “Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations ...

NEW HAVEN, Conn. (WTNH) — News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing. According to the Pew Research Center, overall, 18% ...

The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according ...

The National Academies of Sciences, Engineering, and Medicine Committee on Sickle Cell Disease in Social Security Disability Evaluations is inviting people with sickle cell disease (SCD) and ...

CHARLESTON, S.C. (WCSC) - The Medical University of South Carolina is expanding its access to state-supported Sickle Cell programs for “warriors,” or patients battling the disease. The medical ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to treat sickle cell disease (SCD). The trial aims to ...